41 results
8-K
EX-99.1
NEO
Neogenomics Inc.
30 Jul 09
Entry into a Material Definitive Agreement
12:00am
be expanded, under certain circumstances, to include up to two additional tests for other cancers.
According to the American Cancer Society
8-K
EX-99.1
NEO
Neogenomics Inc.
28 Apr 20
NeoGenomics Reports 11% Revenue Growth to $106 Million
8:15am
a disruption in Oncology care like many other areas of our society. And while our business is not immune from the impact of COVID-19, it is certainly
8-K
EX-99.2
NEO
Neogenomics Inc.
6 Aug 18
NeoGenomics Announces Proposed Public Offering of Common Stock
4:42pm
Society of Hematology 2017 – 2 oral presentations MDS Extended FISH Panel NRAS Mutation Analysis NeoLAB Myeloid Disorders Profile genes) KRAS Mutation
8-K
EX-99.1
NEO
Neogenomics Inc.
4 Nov 21
NeoGenomics Reports Revenue of $121 Million
7:23am
and the Company presented new data in early breast cancer at the European Society for Medical Oncology (ESMO) Congress, highlighting RaDaR™ as a highly
8-K
EX-99.1
NEO
Neogenomics Inc.
10 Aug 21
Regulation FD Disclosure
5:09pm
Types Creates a ~$15Bn+ Opportunity 29 80% to 85% of all cancer patients are treated by community oncologistsSource: American Cancer Society – Facts
8-K
EX-99.1
2gl0r95chq pe8j
25 May 18
Regulation FD Disclosure
5:06pm
8-K
EX-10.1
d8ydik
2 Dec 19
Departure of Directors or Certain Officers
5:07pm
424B3
3augadwu
14 Apr 11
Prospectus supplement
12:00am
424B3
24sgmyndnoq
18 May 09
Prospectus supplement
12:00am
POS AM
xuh5p6 a6kfeqm
28 Apr 09
Prospectus update (post-effective amendment)
12:00am
424B3
5pibdcq 9a
13 May 10
Prospectus supplement
12:00am
424B3
d0wb0sgu2b 99mdoize
20 May 10
Prospectus supplement
12:00am
424B3
nt5rqt36r
14 Apr 11
Prospectus supplement
12:00am